Fragile X syndrome: From molecular genetics to therapy

Department of Medical Genetics, University of Antwerp, Antwerp, Belgium.
Journal of Medical Genetics (Impact Factor: 6.34). 10/2009; 46(9):577-84. DOI: 10.1136/jmg.2008.064667
Source: PubMed


Fragile X syndrome, the main cause of inherited mental retardation, is caused by transcriptional silencing of the fragile X mental retardation gene, FMR1. Absence of the associated protein FMRP leads to the dysregulation of many genes creating a phenotype of ADHD, anxiety, epilepsy and autism. The core aim of this review is to summarise two decades of molecular research leading to the characterisation of cellular and molecular pathways involved in the pathology of this disease and as a consequence to the identification of two new promising targets for rational therapy of fragile X syndrome, namely the group 1 metabotrope glutamate receptors (Gp1 mGluRs) and the gamma-amino butyric acid A receptors (GABA(A)Rs). As no current clinical treatments are directed specifically at the underlying neuronal defect due to absence of FMRP, this might open new powerful therapeutic strategies.

Download full-text


Available from: Charlotte D'Hulst, Mar 11, 2015
  • Source
    • "FRDA is one of several diseases caused by triplet repeats located in non-coding regions. One important example of these tri-nucleotide repeat diseases is the neuropsychiatric disorder Fragile X syndrome, where a CGG@BULLETCCG tract resides within the 5′ UTR of the Fragile X mental retardation 1 (FMR1) gene (Pieretti et al. 1991; D'Hulst and Kooy 2009). DNA methylation, heterochromatic histone marks (e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This is an exciting time in the study of Friedreich's ataxia. Over the last 10 years much progress has been made in uncovering the mechanisms, whereby the Frataxin gene is silenced by (GAA)n repeat expansions and several of the findings are now ripe for testing in the clinic. The discovery that the Frataxin gene is heterochromatinised and that this can be antagonised in vivo has led to the tantalizing possibility that the disease might be amenable to a more radical therapeutic approach involving epigenetic modifiers. Here, we set out to review progress in the understanding of the fundamental mechanisms whereby genes are regulated at this level and how these findings have been applied to achieve a deeper understanding of the dysregulation that occurs as the primary genetic lesion in Friedreich's ataxia.
    Journal of Neurochemistry 08/2013; 126(s1). DOI:10.1111/jnc.12254 · 4.28 Impact Factor
  • Source
    • "Extensive functional analysis of these neurons shows that FMR1 down-regulation leads to the formation of neurons with poor synaptic capability and lack of response to glutamate. FMR1 expression was already shown to be restricted mainly to the central nervous system during human embryogenesis (Abitbol et al., 1993), and its absence was shown to be coupled with abnormal neurogenesis (Castren, 2006; D'Hulst and Kooy, 2009). However, the spatiotemporal sequence of events linking between gradual down-regulation of FMR1 and abnormal neurogenesis are difficult to observe in KO animal models, since FMR1 expression is absent in these animals even at early stages of development. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability, caused by developmentally regulated inactivation of FMR1, leading to the absence of its encoded protein FMRP. We have previously shown that undifferentiated Fragile X human Embryonic Stem Cells (FX-hESCs) express FMRP, despite the presence of the full FMR1 mutation (>200 CGG repeats). We describe here, for the first time, in-vitro differentiation of FX-hESCs into neurons progressively inactivating FMR1. Abnormal neurogenesis and aberrant gene expression were found already during early stages of differentiation, leading to poor neuronal maturation and high gliogenic development. Human FX neurons fired action potentials but displayed poor spontaneous synaptic activity and lacked reactivity to glutamate. Our dynamic FX-hESCs model can contribute to the understanding of the sequence of developmental events taking place during neurogenesis and how they are altered in FXS individuals, leading to intellectual disability. Furthermore, it can shed light over the striking phenotypic features characterizing FXS in human.
    Developmental Biology 12/2012; 374(1). DOI:10.1016/j.ydbio.2012.11.031 · 3.55 Impact Factor
  • Source
    • "Current knowledge surrounding the pathophysiology of FXS has been greatly advanced by the development of animal models [95]. These transgenic animals do not carry the trinucleotide expansion but do have functional deletions of FMRP. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A growing body of research indicates a pivotal role for astrocytes at the developing synapse. In particular, astrocytes are dynamically involved in governing synapse structure, function, and plasticity. In the postnatal brain, their appearance at synapses coincides with periods of developmental plasticity when neural circuits are refined and established. Alterations in the partnership between astrocytes and neurons have now emerged as important mechanisms that underlie neuropathology. With overall synaptic function standing as a prominent link to the expression of the disease phenotype in a number of neurodevelopmental disorders and knowing that astrocytes influence synapse development and function, this paper highlights the current knowledge of astrocyte biology with a focus on their involvement in fragile X syndrome.
    Neural Plasticity 07/2012; 2012(2090-5904):197491. DOI:10.1155/2012/197491 · 3.58 Impact Factor
Show more